5-Azacytidine
Based on 139 publication(s) in Google Scholar
5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes. 5-Azacytidine induces cell autophagy.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.03%
- CAS. Nr.: 320-67-2
- Formel: C8H12N4O5
- Molecular Weight:244.20
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Stem Cell Signaling Compound Library
HY-L017
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
Nucleotide Compound Library
HY-L044
-
Antibacterial Compound Library
HY-L049
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Anti-Lung Cancer Compound Library
HY-L075
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Transcription Factor-Targeted Library
HY-L090
-
Tumorigenesis-Related Compound Library
HY-L100
-
Rare Diseases Drug Library
HY-L102
-
Chemotherapy Drug Library
HY-L112
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Off-patent Drug Library
HY-L141
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Methylation Compound Library
HY-L203
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Anti-Cancer Approved Drug Library
HY-L213
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Posttranslational Modification Library
HY-L226
-
RNA Binding Bioactive Compound Library
HY-L248
Publications Citing Use of MedChemExpress (MCE) 5-Azacytidine
More- Nature. 2025 Jan;637(8045):461-469. [Abstract]
- Science. 2026 Mar 12;391(6790):1130-1137. [Abstract]
- Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
- Drug Resist Updat. 2024 Jul 22:76:101120. [Abstract]
- Cell Stem Cell. 2026 Jun 4;33(6):982-999.e8. [Abstract]
- Mol Cell. 2022 Oct 20;82(20):3901-3918.e7. [Abstract]
- Cancer Res. 2020 Feb 1;80(3):406-417. [Abstract]
- Sci Immunol. 2026 Jun 26;11(120):eadz4302. [Abstract]
- ACS Nano. 2024 Jul 22. [Abstract]
- Nat Commun. 2023 Sep 19;14(1):5709. [Abstract]
- Nat Commun. 2022 May 13;13(1):2672. [Abstract]
- Cell Death Differ. 2026 May 25. [Abstract]
- Adv Sci (Weinh). 2025 Mar 24:e2501623. [Abstract]
- Adv Sci (Weinh). 2024 Nov;11(44):e2401931. [Abstract]
- Adv Sci (Weinh). 2024 May;11(19):e2307940. [Abstract]
- Leukemia. 2021 Dec;35(12):3430-3443. [Abstract]
- Theranostics. 2021 Jan 1;11(5):2318-2333. [Abstract]
- J Adv Res. 2025 May 21:S2090-1232(25)00358-3. [Abstract]
- J Exp Clin Cancer Res. 2025 Apr 7;44(1):114. [Abstract]
- J Exp Clin Cancer Res. 2023 May 19;42(1):127. [Abstract]
- Sci Adv. 2024 Apr 26;10(17):eadm7164. [Abstract]
- Sci Adv. 2024 Apr 19;10(16):eadi1782. [Abstract]
- Redox Biol. 2026 Jul:94:104188. [Abstract]
- Redox Biol. 2026 Mar:90:104034. [Abstract]
- EBioMedicine. 2024 Jul:105:105177. [Abstract]
- Cell Rep Med. 2025 Dec 29:102526. [Abstract]
- J Immunother Cancer. 2025 Sep 22;13(9):e011893. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Cell Rep Med. 2024 May 16:101580. [Abstract]
- Clin Cancer Res. 2024 Nov 15;30(22):5166-5179. [Abstract]
- Cancer Lett. 2026 Mar 28:218465. [Abstract]
- Mol Psychiatry. 2026 Feb 26. [Abstract]
- Cancer Lett. 2025 Aug 29:633:218010. [Abstract]
- Cell Death Dis. 2024 Aug 27;15(8):627. [Abstract]
- Acta Biomater. 2023 Jul 1:164:407-421. [Abstract]
- Cell Death Dis. 2018 Apr 27;9(5):497. [Abstract]
- Cell Death Dis. 2018 Jan 26;9(2):129. [Abstract]
- Proc Natl Acad Sci U S A. 2024 Apr 2;121(14):e2321611121. [Abstract]
- Nano Lett. 2023 Oct 25;23(20):9437-9444. [Abstract]
- Cell Commun Signal. 2019 Aug 14;17(1):94. [Abstract]
- Int J Biol Macromol. 2026 Apr 9:360:151944. [Abstract]
- Int J Biol Macromol. 2022 Dec 31;223(Pt A):916-930. [Abstract]
- Acta Pharmacol Sin. 2022 Feb;43(2):457-469. [Abstract]
- New Phytol. 2026 Aug;251(3):1415-1434. [Abstract]
- NPJ Breast Cancer. 2023 Aug 11;9(1):66. [Abstract]
- Oncogene. 2025 Sep;44(34):3096-3112. [Abstract]
- Oncogene. 2021 Apr;40(15):2711-2724. [Abstract]
- Cell Rep. 2025 Nov 25;44(11):116496. [Abstract]
- Arch Toxicol. 2024 May;98(5):1499-1513. [Abstract]
- Cell Rep. 2023 Aug 1;42(8):112927. [Abstract]
- Sci Data. 2022 Oct 8;9(1):610. [Abstract]
- Clin Transl Med. 2026 Feb;16(2):e70603. [Abstract]
- Clin Transl Med. 2025 Jul;15(7):e70380. [Abstract]
- Anal Chem. 2026 Jun 30;98(25):19057-19069. [Abstract]
- Mol Metab. 2026 Jun 17:110:102402. [Abstract]
- Elife. 2023 Nov 6:12:e92142. [Abstract]
- Comput Biol Med. 2024 Feb:169:107889. [Abstract]
- Cell Mol Life Sci. 2023 Oct 28;80(11):338. [Abstract]
- Antioxid Redox Signal. 2021 Jul;35(1):1-20. [Abstract]
- Ecotoxicol Environ Saf. 2020 Dec 1;205:111089. [Abstract]
- Cancer Cell Int. 2024 Jun 13;24(1):208. [Abstract]
- Cell Biol Toxicol. 2024 Dec 21;41(1):9. [Abstract]
- J Exp Bot. 2025 Jan 7:erae508. [Abstract]
- Biochem Pharmacol. 2025 Jan 27:116784. [Abstract]
- Commun Biol. 2024 Dec 19;7(1):1649. [Abstract]
- Respir Res. 2025 Sep 29;26(1):275. [Abstract]
- aBIOTECH. 2025 Jul 16;6(3):441-451. [Abstract]
- PLoS Pathog. 2024 Nov 25;20(11):e1012736. [Abstract]
- Int J Mol Sci. 2023 Mar 20;24(6):5896. [Abstract]
- PLoS Pathog. 2020 Mar 24;16(3):e1008429. [Abstract]
- Pharmaceuticals (Basel). 2021 Jul 30;14(8):749. [Abstract]
- mBio. 2025 Dec 10;16(12):e0255425. [Abstract]
- Eur J Pharmacol. 2025 Sep 15:1003:177942. [Abstract]
- Am J Physiol Cell Physiol. 2024 Oct 1;327(4):C1125-C1142. [Abstract]
- Int Immunopharmacol. 2022 Oct:111:109113. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Am J Sports Med. 2023 Nov;51(13):3533-3545. [Abstract]
- BMC Biol. 2021 Sep 7;19(1):192. [Abstract]
- Mol Oncol. 2018 Feb;12(2):180-195. [Abstract]
- Cancers (Basel). 2025 Dec 9;17(24):3936. [Abstract]
- Cancers (Basel). 2023 Jan 8;15(2):417. [Abstract]
- Cancer Sci. 2026 May 18. [Abstract]
- Front Cell Dev Biol. 2021 Apr 30:9:667435. [Abstract]
- FASEB J. 2026 Apr 15;40(7):e71755. [Abstract]
- FASEB J. 2026 Jan 31;40(2):e71426. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- iScience. 2024 May 3;27(6):109869. [Abstract]
- Nutr Metab. 2020 May 27;17:41. [Abstract]
- Sci Rep. 2026 Jan 14;16(1):5201. [Abstract]
- Sci Rep. 2023 Nov 9;13(1):19438. [Abstract]
- ACS Infect Dis. 2025 Oct 30. [Abstract]
- Dig Liver Dis. 2022 Jul;54(7):937-945. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- ACS Pharmacol Transl Sci. 2024 Jul 30;7(8):2484-2495. [Abstract]
- Brain Res Bull. 2024 Jun 15:212:110954. [Abstract]
- Heliyon. 2024 Aug 10;10(16):e36017. [Abstract]
- Hum Genet. 2024 Mar;143(3):385-399. [Abstract]
- Ann Clin Microbiol Antimicrob. 2023 Jun 26;22(1):49. [Abstract]
- Clin Exp Med. 2025 Jul 30;25(1):267. [Abstract]
- Mol Carcinog. 2023 Aug;62(8):1119-1135. [Abstract]
- Funct Integr Genomics. 2024 Sep 17;24(5):161. [Abstract]
- PPAR Res. 2021 Apr 16:2021:6663782. [Abstract]
- Breast Cancer Res Treat. 2023 Nov;202(2):397-408. [Abstract]
- Discov Oncol. 2024 Jun 27;15(1):248. [Abstract]
- Genes (Basel). 2023 Oct 8;14(10):1916. [Abstract]
- Invest New Drugs. 2022 Aug;40(4):738-746. [Abstract]
- SLAS Discov. 2018 Aug;23(7):687-696. [Abstract]
- PLoS One. 2019 Sep 6;14(9):e0222298. [Abstract]
- Anal Biochem. 2024 Dec 3:115741. [Abstract]
- J Pediatr Surg. 2023 Jul;58(7):1317-1321. [Abstract]
- Gene. 2024 Jan 20:892:147887. [Abstract]
- Arch Oral Biol. 2025 Aug:176:106296. [Abstract]
- Int J Hematol. 2025 Feb;121(2):194-205. [Abstract]
- Biochem Genet. 2025 Dec 16. [Abstract]
- J Int Med Res. 2024 Mar;52(3):3000605241234567. [Abstract]
- bioRxiv. 2026 May 26:2026.05.22.726988. [Abstract]
- bioRxiv. 2025 Oct 8.
- bioRxiv. 2025 Aug 27.
- bioRxiv. 2025 Jul 12:2025.07.08.663754. [Abstract]
- Patent. US20250152731A1.
- bioRxiv. 2025 Mar 17:2025.03.14.642839. [Abstract]
- Patent. US20240344035A1
- University of Pittsburgh. 2024.
- Patent. US20240344035A1.
- University of Düsseldorf. 2024.
- Research Square Preprint. 2024 Jan 3.
- bioRxiv. 2023 Nov 23.
- SSRN. 2023 Sep 8.
- SSRN. 2023 Jul 7.
- bioRxiv. 2023 Feb 7.
- bioRxiv. 2023 Jan 9.
- Research Square Print. September 9th, 2022.
- Dis Markers. 2022 Jul 11:2022:7926483. [Abstract]
- Research Square Preprint. 2021 Jun.
- Research Square Preprint. 2021 Feb.
- University of Colorado. 2020 Dec.
- Ann Transl Med. 2020 Mar;8(6):329. [Abstract]
- Ann Transl Med. 2020 Mar;8(6):373. [Abstract]
- Patent. US20180263995A1.
Customer Validation & Images
-
RT-PCR
-
WB
-
RT-PCR
-
RT-PCR
-
WB
Alle DNA Methyltransferase Isoform-spezifische Produkte anzeigen
MoreAlle Antibiotic Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
DNMT1 |
Nucleoside Antimetabolite/Analog |
Autophagy |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 5637 | IC50 |
1.73 μM
Compound: 5-Aza-cytidine
|
Antiproliferative activity against human 5637 cells after 96 hrs by crystal violet assay
Antiproliferative activity against human 5637 cells after 96 hrs by crystal violet assay
|
[PMID: 18434163] |
| A-427 | IC50 |
0.63 μM
Compound: 5-Aza-cytidine
|
Antiproliferative activity against human A427 cells after 96 hrs by crystal violet assay
Antiproliferative activity against human A427 cells after 96 hrs by crystal violet assay
|
[PMID: 18434163] |
| HEK293 | IC50 |
>500 μM
Compound: azacitidine
|
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
|
[PMID: 23241029] |
| HT-29 | IC50 |
3800 nM
Compound: 5-azacytidine
|
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
|
[PMID: 2778449] |
| KB | IC50 |
0.23 μg/mL
Compound: 80
|
Growth inhibition of human KB cells
Growth inhibition of human KB cells
|
[PMID: 29135244] |
| KYSE-70 cell line | IC50 |
1.59 μM
Compound: 5-Aza-cytidine
|
Antiproliferative activity against human KYSE70 cells after 96 hrs by crystal violet assay
Antiproliferative activity against human KYSE70 cells after 96 hrs by crystal violet assay
|
[PMID: 18434163] |
| MCF7 | IC50 |
6.78 μM
Compound: 5-Aza-cytidine
|
Antiproliferative activity against human MCF7 cells after 96 hrs by crystal violet assay
Antiproliferative activity against human MCF7 cells after 96 hrs by crystal violet assay
|
[PMID: 18434163] |
| P388 | IC50 |
5 μM
Compound: 5-azacytidine
|
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
|
[PMID: 2778449] |
Unmethylated CpG islands associated with a variety of genes become partially or fully methylated in tumors and can be reactivated by 5-Azacytidine[1]. 5-Azacytidine acts as weak inducers of erythroid differentiation of Friend erythroleukemia cells in the same concentration range where they affect DNA methyltransferase activity[2]. 5-Azacytidine inhibits L1210 cells with ID50 and ID90 values of 0.019 and circa 0.15 μg/mL, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 320-67-2
-
Appearance Solid
-
Molecular Weight 244.20
-
Formel C8H12N4O5
-
Color White to yellow
-
SMILES
OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)N=C2)=O)O1
-
Synonyms
Azacitidine; 5-AzaC; Ladakamycin
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (139)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Jan;637(8045):461-469. PMID: 39743585
5-Azacytidine purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jan;637(8045):461-469. [Abstract]
5-Azacytidine (5 μM, 5 days) reverses FBP1 promoter methylation and restores FBP1 protein levels in SK-HEP-1 and HepG2 cells.
-
Science
2026 Mar 12;391(6790):1130-1137. PMID: 41411409 -
Mol Cancer
hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma. [Abstract]2023 Dec 4;22(1):195. PMID: 38044421
5-Azacytidine purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
5-Azacytidine (5µM; 72 h) increases the expression of LIG1 in GEM-resistant cells.
-
Drug Resist Updat
2024 Jul 22:76:101120. PMID: 39053383
5-Azacytidine purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Jul 22:76:101120. [Abstract]
Western blot were conducted to examine the BCL7A levels in AML cells treated with different concentrations of 5-AzaC (5-Azacytidine) (0, 20, 40 μM).
-
Cell Stem Cell
Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. [Abstract]2026 Jun 4;33(6):982-999.e8. PMID: 42102807 -
Mol Cell
2022 Oct 20;82(20):3901-3918.e7. PMID: 36206767 -
Cancer Res
ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression. [Abstract]2020 Feb 1;80(3):406-417. PMID: 32015157 -
Sci Immunol
Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. [Abstract]2026 Jun 26;11(120):eadz4302. PMID: 42361199 -
ACS Nano
Dual-Responsive Epigenetic Inhibitor Nanoprodrug Combined with Oncolytic Virus Synergistically Boost Cancer Immunotherapy by Igniting Gasdermin E-Mediated Pyroptosis. [Abstract]2024 Jul 22. PMID: 39038109 -
Nat Commun
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. [Abstract]2023 Sep 19;14(1):5709. PMID: 37726279 -
Nat Commun
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. [Abstract]2022 May 13;13(1):2672. PMID: 35562334 -
Cell Death Differ
GSDME acts as an epigenetic modifier to promote melanoma development via centriole biogenesis regulator PLK4. [Abstract]2026 May 25. PMID: 42185629 -
Adv Sci (Weinh)
Methionine Metabolism Dictates PCSK9 Expression and Antitumor Potency of PD-1 Blockade in MSS Colorectal Cancer. [Abstract]2025 Mar 24:e2501623. PMID: 40125618 -
Adv Sci (Weinh)
The Thyroid Hormone Analog GC-1 Mitigates Acute Lung Injury by Inhibiting M1 Macrophage Polarization. [Abstract]2024 Nov;11(44):e2401931. PMID: 39373388 -
Adv Sci (Weinh)
In Situ Formation of Fibronectin-Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy. [Abstract]2024 May;11(19):e2307940. PMID: 38482976 -
Leukemia
STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation. [Abstract]2021 Dec;35(12):3430-3443. PMID: 34075200 -
Theranostics
Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma. [Abstract]2021 Jan 1;11(5):2318-2333. PMID: 33500727 -
J Adv Res
Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysis. [Abstract]2025 May 21:S2090-1232(25)00358-3. PMID: 40409464 -
J Exp Clin Cancer Res
Tetrahydrobenzimidazole TMQ0153 targets OPA1 and restores drug sensitivity in AML via ROS-induced mitochondrial metabolic reprogramming. [Abstract]2025 Apr 7;44(1):114. PMID: 40197337 -
J Exp Clin Cancer Res
Epigenetically silenced lncRNA SNAI3-AS1 promotes ferroptosis in glioma via perturbing the m6A-dependent recognition of Nrf2 mRNA mediated by SND1. [Abstract]2023 May 19;42(1):127. PMID: 37202791 -
Sci Adv
Bioactive fiber-reinforced hydrogel to tailor cell microenvironment for structural and functional regeneration of myotendinous junction. [Abstract]2024 Apr 26;10(17):eadm7164. PMID: 38657071 -
Sci Adv
RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells. [Abstract]2024 Apr 19;10(16):eadi1782. PMID: 38630819 -
Redox Biol
DNMT1-DUOXA1 axis discovers a novel methylation-ferroptosis circuit in bicalutamide-resistant prostate cancer. [Abstract]2026 Jul:94:104188. PMID: 42097033 -
Redox Biol
Methylation reader MBD2-mediated GPX4 transcriptional repression drives ovarian granulosa cell ferroptosis in PCOS. [Abstract]2026 Mar:90:104034. PMID: 41576700 -
EBioMedicine
Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma. [Abstract]2024 Jul:105:105177. PMID: 38924839 -
Cell Rep Med
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia. [Abstract]2025 Dec 29:102526. PMID: 41468895 -
J Immunother Cancer
2025 Sep 22;13(9):e011893. PMID: 40987494 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Cell Rep Med
Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. [Abstract]2024 May 16:101580. PMID: 38776913 -
Clin Cancer Res
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. [Abstract]2024 Nov 15;30(22):5166-5179. PMID: 39269307 -
Cancer Lett
HOX code-based stratification reveals RUNX1T1-HDAC reprogramming as a targetable driver of lineage plasticity across cancers. [Abstract]2026 Mar 28:218465. PMID: 41912135 -
Mol Psychiatry
The novel role of GADD45A in the etiology of autism: modulating neuronal excitability via TET1/R-loop dependent regulation of KCNQ5. [Abstract]2026 Feb 26. PMID: 41741708 -
Cancer Lett
Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. [Abstract]2025 Aug 29:633:218010. PMID: 40886822 -
Cell Death Dis
CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator. [Abstract]2024 Aug 27;15(8):627. PMID: 39191721 -
Acta Biomater
A Supramolecular Assembly Strategy for Hydrophilic Drug Delivery towards Synergistic Cancer Treatment. [Abstract]2023 Jul 1:164:407-421. PMID: 37088157 -
Cell Death Dis
Interaction of the primordial germ cell-specific protein C2EIP with PTCH2 directs differentiation of embryonic stem cells via HH signaling activation. [Abstract]2018 Apr 27;9(5):497. PMID: 29703892 -
Cell Death Dis
Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. [Abstract]2018 Jan 26;9(2):129. PMID: 29374157
5-Azacytidine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Jan 26;9(2):129. [Abstract]
The effects of treatment with the indicated epigenetic inhibitors on cleaved PARP (Clv-PARP) expression in both PC9/ER and HCC827/ER cells. β-actin is used as a loading control.
-
Proc Natl Acad Sci U S A
NSUN5/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion. [Abstract]2024 Apr 2;121(14):e2321611121. PMID: 38547058 -
Nano Lett
2023 Oct 25;23(20):9437-9444. PMID: 37818841 -
Cell Commun Signal
Increased HERV-E clone 4-1 expression contributes to DNA hypomethylation and IL-17 release from CD4+ T cells via miR-302d/MBD2 in systemic lupus erythematosus. [Abstract]2019 Aug 14;17(1):94. PMID: 31412880 -
Int J Biol Macromol
TIMP1 and PKM drive immunosuppression and metabolic remodeling to promote colorectal cancer progression through integrated multi-omics analysis. [Abstract]2026 Apr 9:360:151944. PMID: 41966374 -
Int J Biol Macromol
Interactive regulation of DNA demethylase gene TET1 and m6A methyltransferase gene METTL3 in myoblast differentiation. [Abstract]2022 Dec 31;223(Pt A):916-930. PMID: 36375665
5-Azacytidine purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2022 Dec 31;223(Pt A):916-930. [Abstract]
5-azacytidine (5-AzaC; 5 μM; 1, 2, 3 days) results in an increase in the expression of MYOD1 and MYOG during myoblast differentiation.
-
Acta Pharmacol Sin
2022 Feb;43(2):457-469. PMID: 33850273 -
New Phytol
Promoter methylation of MdRNS3a contributes to Alternaria leaf spot resistance in apple (Malus × domestica). [Abstract]2026 Aug;251(3):1415-1434. PMID: 42204126 -
NPJ Breast Cancer
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. [Abstract]2023 Aug 11;9(1):66. PMID: 37567892 -
Oncogene
ACSL5 regulated acetyl-CoA to promote bladder cancer cellular senescence via 53BP1 acetylation. [Abstract]2025 Sep;44(34):3096-3112. PMID: 40595416 -
Oncogene
2021 Apr;40(15):2711-2724. PMID: 33712705 -
Cell Rep
A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential. [Abstract]2025 Nov 25;44(11):116496. PMID: 41166305 -
Arch Toxicol
Cellular senescence gene TACC3 associated with colorectal cancer risk via genetic and DNA methylated alteration. [Abstract]2024 May;98(5):1499-1513. PMID: 38480537 -
Cell Rep
DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype. [Abstract]2023 Aug 1;42(8):112927. PMID: 37537841 -
Sci Data
High-content, arrayed compound screens with rhinovirus, influenza A virus and herpes simplex virus infections. [Abstract]2022 Oct 8;9(1):610. PMID: 36209289 -
Clin Transl Med
2026 Feb;16(2):e70603. PMID: 41603084 -
Clin Transl Med
T-cell differentiation stage block bias confers hypermethylation and mediastinal preference in T-cell lymphoblastic lymphoma. [Abstract]2025 Jul;15(7):e70380. PMID: 40579780 -
Anal Chem
upsFISH: An Occupancy-Reporting Fluorescence In Situ Hybridization Method for Single-Cell Detection of Chromatin Interactions. [Abstract]2026 Jun 30;98(25):19057-19069. PMID: 42322584 -
Mol Metab
Venetoclax and hypomethylating agents synergize to increase cell death and metabolic remodeling in acute B-lymphoblastic leukemia cells. [Abstract]2026 Jun 17:110:102402. PMID: 42309255 -
Elife
GLI1 facilitates collagen-induced arthritis in mice by collaborative regulation of DNA methyltransferases. [Abstract]2023 Nov 6:12:e92142. PMID: 37929702 -
Comput Biol Med
2024 Feb:169:107889. PMID: 38199214 -
Cell Mol Life Sci
2023 Oct 28;80(11):338. PMID: 37897534 -
Antioxid Redox Signal
Oxidative Stress-Induced Hypermethylation of KLF5 Promoter Mediated by DNMT3B Impairs Osteogenesis by Diminishing the Interaction with β-Catenin. [Abstract]2021 Jul;35(1):1-20. PMID: 33588625 -
Ecotoxicol Environ Saf
Waterborne copper exposure up-regulated lipid deposition through the methylation of GRP78 and PGC1α of grass carp Ctenopharyngodon idella. [Abstract]2020 Dec 1;205:111089. PMID: 32810645 -
Cancer Cell Int
DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma. [Abstract]2024 Jun 13;24(1):208. PMID: 38872157 -
Cell Biol Toxicol
M6A modification-mediated LIMA1 promotes the progression of hepatocellular carcinoma through the wnt-βcatenin/Hippo pathway. [Abstract]2024 Dec 21;41(1):9. PMID: 39707043 -
J Exp Bot
A genome-wide survey of DNA methylation reveals hyper-methylation regulates after-ripening and dormancy of recalcitrant Panax notoginseng seeds. [Abstract]2025 Jan 7:erae508. PMID: 39774902 -
Biochem Pharmacol
GRHL3 drives radiotherapy resistance and blocks the anti-tumor response of NK and CD4+ T cells in lung squamous cell carcinoma via RNF2. [Abstract]2025 Jan 27:116784. PMID: 39880318 -
Commun Biol
Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells. [Abstract]2024 Dec 19;7(1):1649. PMID: 39702755 -
Respir Res
ZNF184-mediated transcriptional activation of SAE1 drives the cell cycle entry and immune evasion in non-small cell lung cancer. [Abstract]2025 Sep 29;26(1):275. PMID: 41024125 -
aBIOTECH
Epigenetic regulation of JASMONATE ZIM-DOMAIN genes contributes to heat tolerance in the heat-tolerant rice cultivar Nagina 22. [Abstract]2025 Jul 16;6(3):441-451. PMID: 40994445 -
PLoS Pathog
2024 Nov 25;20(11):e1012736. PMID: 39585924 -
Int J Mol Sci
2023 Mar 20;24(6):5896. PMID: 36982968 -
PLoS Pathog
BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses. [Abstract]2020 Mar 24;16(3):e1008429. PMID: 32208449 -
Pharmaceuticals (Basel)
2021 Jul 30;14(8):749. PMID: 34451846 -
mBio
Human-specific activation of the DUX4-SLC34A2 axis by herpesviruses suppresses antiviral innate immunity. [Abstract]2025 Dec 10;16(12):e0255425. PMID: 41211819 -
Eur J Pharmacol
VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors. [Abstract]2025 Sep 15:1003:177942. PMID: 40651787 -
Am J Physiol Cell Physiol
Hypomethylation-associated ELF3 helps nasopharyngeal carcinoma to escape immune surveillance via MUC16-mediated glycolytic metabolic reprogramming. [Abstract]2024 Oct 1;327(4):C1125-C1142. PMID: 39219440 -
Int Immunopharmacol
2022 Oct:111:109113. PMID: 35944462 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Am J Sports Med
Inhibition of IKKβ via a DNA-Based In Situ Delivery System Improves Achilles Tendinopathy Healing in a Rat Model. [Abstract]2023 Nov;51(13):3533-3545. PMID: 37804159 -
BMC Biol
A pair of long intergenic non-coding RNA LINC00887 variants act antagonistically to control Carbonic Anhydrase IX transcription upon hypoxia in tongue squamous carcinoma progression. [Abstract]2021 Sep 7;19(1):192. PMID: 34493285 -
Mol Oncol
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. [Abstract]2018 Feb;12(2):180-195. PMID: 29130642 -
Cancers (Basel)
DNMT3B Knockdown Enhances PARP Inhibitor Sensitivity in Biliary Tract Cancer Cells via Opioid Growth Factor Receptor-Mediated Homologous Recombination Impairment. [Abstract]2025 Dec 9;17(24):3936. PMID: 41463187 -
Cancers (Basel)
RETRACTED: TRIM10 Is Downregulated in Acute Myeloid Leukemia and Plays a Tumor Suppressive Role via Regulating NF-κB Pathway. [Abstract]2023 Jan 8;15(2):417. PMID: 36672365 -
Cancer Sci
Integrated Transcriptomic and Functional Analyses Reveal lncRNA-miRNA-mRNA Axis in AML Relapse After Allo-HSCT. [Abstract]2026 May 18. PMID: 42151054 -
Front Cell Dev Biol
2021 Apr 30:9:667435. PMID: 33996822 -
FASEB J
2026 Apr 15;40(7):e71755. PMID: 41934343 -
FASEB J
Maternal Fructose Intake During Pregnancy Induced the Hepatic Glucose Homeostasis Imbalance in the Offspring by Inhibiting Glucokinase. [Abstract]2026 Jan 31;40(2):e71426. PMID: 41575313 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
iScience
TERC promotes non-small cell lung cancer progression by facilitating the nuclear localization of TERT. [Abstract]2024 May 3;27(6):109869. PMID: 38799568 -
Nutr Metab
Resveratrol ameliorates atherosclerosis induced by high-fat diet and LPS in ApoE-/- mice and inhibits the activation of CD4+ T cells. [Abstract]2020 May 27;17:41. PMID: 32508962 -
Sci Rep
Interaction between ELMO1 DNA methylation and Med31 promotes H. pylori-induced gastric cancer EMT and intestinal metaplasia via M2 polarization. [Abstract]2026 Jan 14;16(1):5201. PMID: 41535333 -
Sci Rep
Hypermethylation of the CTRP9 promoter region promotes Hcy induced VSMC lipid deposition and foam cell formation via negatively regulating ER stress. [Abstract]2023 Nov 9;13(1):19438. PMID: 37945738 -
ACS Infect Dis
Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights. [Abstract]2025 Oct 30. PMID: 41166549 -
Dig Liver Dis
E2F5 promotes proliferation and invasion of gastric cancer through directly upregulating UBE2T transcription. [Abstract]2022 Jul;54(7):937-945. PMID: 34583905 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
ACS Pharmacol Transl Sci
Epigenetic Targeting of Heparan Sulfate 3- O- and 6- O-Sulfation in Breast Cancer Cells: Prospects for Attenuating Prothrombotic Tumor Cell Activities. [Abstract]2024 Jul 30;7(8):2484-2495. PMID: 39144559 -
Brain Res Bull
MSC-derived exosomes deliver ZBTB4 to mediate transcriptional repression of ITIH3 in astrocytes in spinal cord injury. [Abstract]2024 Jun 15:212:110954. PMID: 38641154 -
Heliyon
PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway. [Abstract]2024 Aug 10;10(16):e36017. PMID: 39229496 -
Hum Genet
Genome-wide analyses reveal the regulatory roles of DNA methylation-regulated alternative promoter transcripts in breast cancer. [Abstract]2024 Mar;143(3):385-399. PMID: 38502355 -
Ann Clin Microbiol Antimicrob
2023 Jun 26;22(1):49. PMID: 37365592 -
Clin Exp Med
2025 Jul 30;25(1):267. PMID: 40736712 -
Mol Carcinog
PRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemia. [Abstract]2023 Aug;62(8):1119-1135. PMID: 37144835 -
Funct Integr Genomics
Tet1-mediated activation of the Ampk signaling by Trpv1 DNA hydroxymethylation exerts neuroprotective effects in a rat model of Parkinson's disease. [Abstract]2024 Sep 17;24(5):161. PMID: 39285026 -
PPAR Res
2021 Apr 16:2021:6663782. PMID: 33959155 -
Breast Cancer Res Treat
FOXO1-regulated lncRNA CYP1B1-AS1 suppresses breast cancer cell proliferation by inhibiting neddylation. [Abstract]2023 Nov;202(2):397-408. PMID: 37640964 -
Discov Oncol
CSRP1 gene: a potential novel prognostic marker in acute myeloid leukemia with implications for immune response. [Abstract]2024 Jun 27;15(1):248. PMID: 38937285 -
Genes (Basel)
The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia. [Abstract]2023 Oct 8;14(10):1916. PMID: 37895265 -
Invest New Drugs
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation. [Abstract]2022 Aug;40(4):738-746. PMID: 35576022 -
SLAS Discov
A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. [Abstract]2018 Aug;23(7):687-696. PMID: 29865911 -
PLoS One
2019 Sep 6;14(9):e0222298. PMID: 31491024 -
Anal Biochem
Development and validation of a sensitive and fast bioanalytical LC-MS/MS assay for the quantitation of venetoclax and azacitidine in Rat Plasma: Application to pharmacokinetic study. [Abstract]2024 Dec 3:115741. PMID: 39638140 -
J Pediatr Surg
Regulation of Shh/Bmp4 Signaling Pathway by DNA Methylation in Rectal Nervous System Development of Fetal Rats with Anorectal Malformation. [Abstract]2023 Jul;58(7):1317-1321. PMID: 36906487 -
Gene
DNMT1-mediated NR3C1 DNA methylation enables transcription activation of connexin40 and augments angiogenesis during colorectal cancer progression. [Abstract]2024 Jan 20:892:147887. PMID: 37813207 -
Arch Oral Biol
Anaphase promoting complex subunit 10 is a potential diagnostic and prognostic biomarker in oral squamous cell carcinoma. [Abstract]2025 Aug:176:106296. PMID: 40408783 -
Int J Hematol
Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB. [Abstract]2025 Feb;121(2):194-205. PMID: 39636331 -
Biochem Genet
Transcription Activation of DEPDC1B Upon EBF1 Loss Contributes to Cell Cycle Progression and Epithelial-Mesenchymal Transition in Colon Adenocarcinoma. [Abstract]2025 Dec 16. PMID: 41402613 -
J Int Med Res
Hypomethylation of the LncRNA H19 promoter accelerates osteogenic differentiation of vascular smooth muscle cells by activating the Erk1/2 pathways. [Abstract]2024 Mar;52(3):3000605241234567. PMID: 38530015 -
bioRxiv
Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States. [Abstract]2026 May 26:2026.05.22.726988. PMID: 42244620 -
-
-
bioRxiv
2025 Jul 12:2025.07.08.663754. PMID: 40672312 -
-
bioRxiv
2025 Mar 17:2025.03.14.642839. PMID: 40166192 -
-
-
-
-
-
-
-
-
-
-
-
Dis Markers
miR-26a-5p Suppresses Wnt/ β-Catenin Signaling Pathway by Inhibiting DNMT3A-Mediated SFRP1 Methylation and Inhibits Cancer Stem Cell-Like Properties of NSCLC. [Abstract]2022 Jul 11:2022:7926483. PMID: 35860691 -
-
-
-
Ann Transl Med
Restoration of TET2 deficiency inhibits tumor growth in head neck squamous cell carcinoma. [Abstract]2020 Mar;8(6):329. PMID: 32355773 -
Ann Transl Med
Identification of aberrantly methylated differentially expressed genes targeted by differentially expressed miRNA in osteosarcoma. [Abstract]2020 Mar;8(6):373. PMID: 32355817 -
Lösungsmittel & Löslichkeit
DMSO : 250 mg/mL (1023.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (102.38 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 20 mg/mL (81.90 mM); Clear solution; Need ultrasonic
Protokoll
A crude cell-free extract is isolated from LI 210 cells in culture by suspension of the cells in a given volume of 0.05mol/LTris-HCl buffer, pH 7.4, and sonic extraction with a Biosonik at 70% maximal output for 30 sec. The supernatant is collected after centrifugation at 105,000 × g for 60 min (4°C) in a Model L Spinco ultracentrifuge. The final protein concentration of the cell-free extracts is approximately 3 mg/mL. The extracts are used as the source of enzymes. Ribonucleotide reductase activity is measured. A unit of enzyme is defined as the amount that catalyzed dCMP synthesis at a rate of 1 mμmole/hr. The assay systems for the measurement of pyrimidine nucleoside (CR) and deoxynucleoside (TdR, CdR) kinases are essentially those described by Chu and Fischer. However, reactions are terminated by heating for 2 min in a boiling water bath, and the phosphorylated derivatives are isolated according to the method of Bach. Fifty-jul aliquots are applied to 1-inch discs of diethylaminoethyl paper, which are then placed in counting vials and eluted with 0.5 mL of 0.5 mol/LPCA. After 1 hr, 12 mL of Diotol are added, and the radioactivity is determined.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Twenty mL of cells (circa 1×104 cells/mL) are pipetted into sterilized culture tubes with screw caps and incubated at 37°C overnight. The experiment is initiated by the addition of 1 mL of 5-Azacytidine (5-azaCR) or medium for a given period (from 0 to 240 min) prior to the addition of 1 mL of metabolite (or medium). Cell growth is determined twice a day for 3 days by means of a Model A Coulter counter. To determine IDSO and ID90 values, 5 mL of L1210 cells (5×103 cells/mL) are incubated with the drug at 37°C for 3 days, and cell growth is determined.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
For the in vivo experiments, leukemic mice (bearing circa 1×103 cells/animal) are given injections i.p. with 0.2 mL of 5-Azacytidine (5-azaCR) of a given concentration. Two hr later, the reaction is started by injecting 0.5 mL of labeled metabolite (TdR-3H or UR-3H, 10 /μCi/12.5 μg). After 1 hr, animals (3 mice/group) are killed by cervical fracture.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (283 KB)
-
SDS (617 KB)
- English - EN (617 KB)
- Français - FR (617 KB)
- Deutsch - DE (617 KB)
- Norwegian - NO (617 KB)
- Español - ES (617 KB)
- Swedish - SV (617 KB)
- Italian - IT (617 KB)
- Korean - KR (617 KB)
- Portuguese - PT (617 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002 Aug 12;21(35):5483-95. [Content Brief]
[2]. Creusot F, et al. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidineand 5-aza-2'-deoxycytidine. J Biol Chem. 1982 Feb 25;257(4):2041-8. [Content Brief]
[3]. Li LH,et al. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970 Nov;30(11):2760-9. [Content Brief]
[4]. Marycz K, et al. 5-Azacytidine and Resveratrol Enhance Chondrogenic Differentiation of Metabolic Syndrome-Derived Mesenchymal Stem Cells by Modulating Autophagy.Oxid Med Cell Longev. 2019 May 12;2019:1523140. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.0950 mL | 20.4750 mL | 40.9500 mL | 102.3751 mL |
| 5 mM | 0.8190 mL | 4.0950 mL | 8.1900 mL | 20.4750 mL | |
| 10 mM | 0.4095 mL | 2.0475 mL | 4.0950 mL | 10.2375 mL | |
| 15 mM | 0.2730 mL | 1.3650 mL | 2.7300 mL | 6.8250 mL | |
| 20 mM | 0.2048 mL | 1.0238 mL | 2.0475 mL | 5.1188 mL | |
| 25 mM | 0.1638 mL | 0.8190 mL | 1.6380 mL | 4.0950 mL | |
| 30 mM | 0.1365 mL | 0.6825 mL | 1.3650 mL | 3.4125 mL | |
| 40 mM | 0.1024 mL | 0.5119 mL | 1.0238 mL | 2.5594 mL | |
| 50 mM | 0.0819 mL | 0.4095 mL | 0.8190 mL | 2.0475 mL | |
| 60 mM | 0.0683 mL | 0.3413 mL | 0.6825 mL | 1.7063 mL | |
| 80 mM | 0.0512 mL | 0.2559 mL | 0.5119 mL | 1.2797 mL | |
| 100 mM | 0.0410 mL | 0.2048 mL | 0.4095 mL | 1.0238 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
5-Azacytidine Related Classifications
HY-10586 Related Classifications
Powered by Bioz